Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Fresno, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Marina Roytman, Dr.
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Marina Roytman, Dr.
Marina Roytman, M.D., FACP, is board certified in Internal Medicine and fellowship trained in Medical Education. Her interests include viral hepatitis, drug induced liver injury, autoimmune hepatitis, and medical education. She has won multiple awards for her presentations on hepatitis and drug induced liver injury.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eiger BioPharmaceuticals
- ID
- NCT03719313
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated